Navigation Links
Governor Corbett: Lancaster County Commercial Lab to Expand, Create 200 New Jobs
Date:7/25/2012

HARRISBURG, Pa., July 25, 2012 /PRNewswire-USNewswire/ -- Governor Tom Corbett announced today that Eurofins Lancaster Laboratories will expand its operations in Pennsylvania by constructing a new laboratory facility in Lancaster County and creating 200 new jobs. 

"Eurofins Lancaster Laboratories is a true Pennsylvania success that continues to grow and create jobs in the region," said Corbett. "Today's announcement means that the company will grow from 844 employees to more than 1,000 employees. The impact on the community is significant and one the commonwealth is proud to support."

Eurofins Lancaster Laboratories will construct a four-story, 78,000-square-foot laboratory building on its existing campus which will be used for biopharmaceutical, pharmaceutical and food testing. The company will invest more than $17 million to build the new facility and purchase new lab equipment. Eurofins Lancaster Laboratories will retain its existing 844 Pennsylvania employees and create at least 200 new jobs within four years.      

The company received a $700,000 funding offer from the Department of Community and Economic Development, including a $300,000 Pennsylvania First grant and $400,000 in Job Creation Tax Credits.    

"We are pleased to announce this significant expansion of our operations in Lancaster County and are very appreciative of the support from the Commonwealth of Pennsylvania. This project is another example of the commitment of Eurofins Scientific to continued growth and investment in its laboratory operations in North America," said Dr. Timothy S. Oostdyk, president, Eurofins Lancaster Laboratories.

The project was coordinated by the Governor's Action Team, or GAT, a group of economic development professionals who work directly with businesses that are considering locating or expanding in Pennsylvania. GAT provides site selection assistance, coordinates the involvement of other state agencies as needed, and packages the appropriate economic development funding for the project.

Founded in 1961, Eurofins Lancaster Laboratories is one of the largest commercial contract laboratories in the world providing comprehensive laboratory services in the pharmaceutical, biopharmaceutical and environmental sciences. The laboratory serves clients from a diverse range of businesses and industries and also serves local and national governments. For more information about Eurofins Lancaster Laboratories, visit www.lancasterlabs.com.

For more information on the Governor's Action Team and other economic development initiatives in Pennsylvania, visit www.newPA.com or call 1-866-466-3972.

Media contacts:

Kelli Roberts, Governor's Office; 717-783-1116
Steven Kratz, DCED; 717-783-1132


'/>"/>
SOURCE Pennsylvania Office of the Governor
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Governor Gregoire and Congressman McDermott Join Novo Nordisk at Opening Event for Type 1 Diabetes Research Center in Seattle
2. Chesapeake Urologys Dr. Brad Lerner, Chief of Urology at Union Memorial Hospital, Honored with Governors Citation for Outstanding Service
3. Hospira and Lancaster General Hospital Honored for Patient Safety Initiatives
4. PAREXEL And Korea Drug Development Fund Announce Alliance To Accelerate Global Drug Development And Commercialization
5. Healthscope to commercially launch Circadians Cancers of Unknown Primary Diagnostic Test
6. Sinovac Reports Progress in EV71 Vaccine Phase III Clinical Trial and Commercialization Preparation Status
7. Frazier Healthcare Acquires U.S. Commercial Pharmaceutical Packaging Operations from Catalent Pharma Solutions
8. Optimer Pharmaceuticals and Specialised Therapeutics Australia Collaborate to Commercialize Fidaxomicin for Clostridium difficile Infection in Australia and New Zealand
9. CMC Biologics Achieves Successful Pre-Approval European GMP Inspection by MHRA for Commercial Manufacturing
10. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
11. Cardium Announces Plans For Commercializaton Of Excellagen® In The Russian Federation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... AMSTERDAM , Sept. 25, 2017   ... Trial Master File solutions, today—from the IQPC Trial ... Amsterdam , NL)—announced that EastHORN Clinical Services ... its clinical programs and TMF management. EastHORN, a ... Montrium,s eTMF platform to increase transparency to enable ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis , the ... chains, has published the first annual edition of its Global CSR Risk ... 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly ... ... Performance Index ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset ... of specialty vendors and unique items from across the nation, this holiday-themed event will ... services offered by the VNA. The boutique will be open Saturday, November 4 ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Planet Fitness, ... the U.S., announced today its plans to open a flagship location in Covington, LA ... the former Rooms To Go store next to Office Depot in the Holiday Square ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... named one of Michigan’s 2017 Best and Brightest in Wellness® by Best and ... Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. ...
Breaking Medicine News(10 mins):